Pooja Himangshu Patel

Dr. Pooja Himangshu Patel


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Cureus
Verified
Journal Article
Open access
MHMichael Horseman
Michael Horseman
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
ATAndrew S. Tenpas
Andrew S. Tenpas
RJRene Verduzco Jr.
Rene Verduzco Jr.
Salim SuraniSalim Surani
Salim Surani
Humans maintain core body temperature via a complicated system of physiologic mechanisms that counteract heat/cold fluctuations from metabolism, exertion, and the environment. Overextension of these mechanisms or disruption of body temperature homeostasis leads to bodily dysfunction, culminating in a syndrome analogous to exertional heat stroke (EHS). The inability of this thermoregulatory process to maintain the body temperature is caused by either thermal stress or certain drugs. EHS is a syndrome characterized by hyperthermia and the activation of systemic inflammation. Several drug-induced hyperthermic syndromes may resemble EHS and share common mechanisms. The purpose of this article is to review the current literature and compare exertional heat stroke (EHS) to three of the most widely studied drug-induced hyperthermic syndromes: malignant hyperthermia (MH), neuroleptic malignant syndrome (NMS), and serotonin syndrome (SS). Drugs and drug classes that have been implicated in these conditions include amphetamines, diuretics, cocaine, antipsychotics, metoclopramide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and many more. Observations suggest that severe or fulminant cases of drug-induced hyperthermia may evolve into an inflammatory syndrome best described as heat stroke. Their underlying mechanisms, symptoms, and treatment approaches will be reviewed to assist in accurate diagnosis, which will impact the management of potentially life-threatening complications.

1 January 2021 in Cureus
Verified
Journal Article
Open access
PDF file
PPPooja Himangshu Patel
Pooja Himangshu Patel
MNMichelle Nguyen
Michelle Nguyen
RRRubi Rodriguez
Rubi Rodriguez
Salim SuraniSalim Surani
Salim Surani
GUGeorge Udeani
George Udeani
Heart failure (HF) is a major public health problem in the United States as well as worldwide. Chronic heart failure is a syndrome of reduced cardiac output resulting from impaired ventricular function, impaired filling, or a combination of both. Associated symptoms include dyspnea, fatigue, and decreased exercise tolerance. HF has a marked effect on morbidity and mortality, given limited therapeutic choices. The first line of therapeutic agents indicated in heart failure are beta-blockers. Other drugs and therapeutic modalities employed in HF treatment include angiotensin-receptor blockers (ARBs), sacubitril (neprilysin inhibitor) combination with the ARB, valsartan, small doses of aldosterone receptor antagonists (ARAs) in the setting of angiotensin-converting enzyme (ACE) inhibitors, and beta-blockers. Additionally, the sodium-glucose transporter-2 inhibitor, dapagliflozin in the setting of ACE inhibitors, ARBs, or sacubitril-valsartan plus beta-blocker have been employed. Other therapeutic modalities have included loop diuretics, digoxin, the hydralazine-isosorbide dinitrate combination, ivabradine, the inotropes, dobutamine, milrinone, and dopamine. Decreased cardiac contractility is central to the systolic HF. Therapeutic agents employed to increase cardiac contractility in HF are limited because of their mechanistic-related adverse effect profiles. Omecamtiv mecarbil (OM) is a first of its class cardiac myosin activator that increases the cardiac contractility by specifically binding to the catalytic S1 domain of cardiac myosin, to be employed in heart failure treatment. This agent has demonstrated benefit in reducing heart rate, peripheral vascular resistance, mean left arterial pressure, and left ventricular end-diastolic pressure in the animal models. Additionally, OM is known to improve systolic wall thickening, stroke volume (SV), and cardiac output (CO). OM increases systolic ejection time (SET), cardiac myocyte fractional shortening without significant increase of LV dP/dtmax, myocardial oxygen consumption, and myocyte intracellular calcium. The benefits of OM have been demonstrated through key trials, as (i) The Acute Treatment with Omecamtiv mecarbil to Increase Contractility in Acute Heart Failure (ATOMIC-AHF), and (ii) The Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial is ongoing and can help provide further clinical data. OM provides a novel mechanism and therapeutic approach to managing patients with HF. Preclinical and clinical data suggest that OM capability can improve cardiac function, decrease ventricular wall stress, reverse ventricular remodeling, and promote sympathetic withdrawal.

28 December 2017 in Hospital Pharmacy
Verified
Journal Article
Closed access
PPPooja Himangshu Patel
Pooja Himangshu Patel
KDKimberly W. Dickerson
Kimberly W. Dickerson
Background: Hospitalizations due to chronic diseases such as heart failure (HF) continue to increase worldwide. Fragmentation of care while transitioning from one care setting to another is an important factor contributing to hospitalizations. Fragmented discharge tools have been implemented; however, the impact of a comprehensive interdisciplinary discharge tool has not been previously studied. Objective: The goal of this study is to assess the impact of the implementation of Project Re-Engineered Discharge (RED) on the incidence of hospital readmissions, all-cause mortality, primary care physician follow-up rate, and cost savings for patients with HF. Methods: This was a single-center, retrospective, cohort study of patients admitted with HF exacerbation at the Central Arkansas Veterans Healthcare System (CAVHS). A random sample of 100 patients admitted prior to implementation of Project RED and 50 patients after Project RED intervention were included in the study. The primary end point was 30-day hospital readmission for HF exacerbation. The co-secondary end points were all-cause mortality, cost savings, and rate of primary care physician appointments scheduled as well as attended per postdischarge recommendations. Results: The 30-day hospital readmission rate was 28% in the pre–Project RED group, and it was 18% in the post–Project RED group (P = .18). The all-cause mortality was significantly lower in the post–Project RED group as compared with the pre–Project RED group (18% vs 41%, P = .04). More patients in the post–Project RED group attended an outpatient primary care appointment as recommended per postdischarge instructions (40% vs 19%, P = .006). In addition, with the decrease in hospital 30-day readmission rate in the post–Project RED group, there was a cost savings of $1453 per patient visit for HF exacerbation. Conclusions: Coordination of care using a discharge tool like Project RED should be utilized in institutions to improve patient outcomes as well as patient safety while decrease the overall health care cost.

1 November 2021 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
SDSandy Diec
Sandy Diec
PPPooja Himangshu Patel
Pooja Himangshu Patel
NSNephy Samuel
Nephy Samuel
JHJose J. Hernandez-Munoz
Jose J. Hernandez-Munoz

14 June 2022 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PPPooja Himangshu Patel
Pooja Himangshu Patel
THTiffany Ho
Tiffany Ho
SUShreeya M. Upadhyay
Shreeya M. Upadhyay
Objective: The objective of this review was to provide dosing recommendations for percentage change in weekly warfarin dose and rates of thrombotic and bleeding events in patients requiring long-term warfarin therapy after bariatric surgery. Data Sources: A comprehensive literature search of PubMed (through April 5, 2021), Cochrane Library, and Google Scholar (through April 5, 2021) databases was completed using the keywords warfarin OR vitamin k antagonist AND bariatric surgery. Study selection and data extraction: Retrospective studies and matched-cohort studies evaluating preoperative and postoperative use of warfarin after bariatric surgery for obesity were considered. Weekly dose defined as sum of daily doses of warfarin for 7 consecutive days was a required outcome to be considered in this review. Patients were excluded from review if post-operative dosage change was not reported. Data synthesis: Six studies were included with a total of 160 patients who met the criteria. A decrease in average warfarin dose was seen in all studies, with the largest decrease occurring at 1 month postsurgery followed by an upward trend toward baseline about 90 days postsurgery. While thrombotic events were observed in none of the patients, there was an increased risk of bleeding in patients, particularly in those who underwent roux-en-y gastric bypass (RYGB) surgery. Relevance to patient care and clinical practice: The study provides a specific warfarin dosing titration regimen, as well as embolic and bleed risk in post-bariatric surgery population. Conclusions: Clinicians may consider lowering warfarin weekly dose by about 25% immediately postsurgery, with doses approaching closer to baseline about 90 days postsurgery.

8 March 2024
Verified
Book Chapter
Open access
PDF file
ATAndrew Tenpas
Andrew Tenpas
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
COChioma Ogbodo
Chioma Ogbodo
JAJoy Alonzo
Joy Alonzo
CPChinonso Paul
Chinonso Paul
Pulmonary hypertension is a condition characterized by elevated blood pressure in pulmonary arteries due to increased muscle mass of vessel walls, leading to arterial constriction and reduced blood oxygenation. Commonly classified into five major groups, pulmonary hypertension is often viewed as quite rare when, in fact, it is far more common than traditionally advertised. It is also an extremely debilitating disease with far-reaching economic, societal, personal, and psychosocial impacts, especially in underserved populations. Though 10 FDA-approved medications—targeting four different biological pathways—have come to market over the last 20 years, more recent research has focused on complex signaling pathways regulating hypoxic and metabolic signaling, proliferation, apoptosis, senescence, and inflammation. In this chapter, we provide an overview of pulmonary hypertension’s prevalence and widespread impact, its underlying pathophysiology and clinical presentations, currently recognized treatment strategies, recommended regimens in special populations, and emerging therapeutic options and fields of research.